Lineage Cell Therapeutics Inc. has announced a significant milestone in its strategic collaboration with Factor Bioscience Inc. Under the partnership, Factor delivered a novel, gene-edited induced pluripotent stem cell (iPSC) line with hypoimmunity edits to Lineage. This proprietary cell line, developed by Factor, is designed to support “off-the-shelf” cell transplant products for non-immune privileged and non-HLA matched indications, and includes a unique disease-specific edit. The delivery of the iPSC line triggered a success payment from Lineage to Factor, with Factor remaining eligible for further payments pending Lineage’s decision to enter into an exclusive license. The collaboration aims to combine Lineage’s cell therapy manufacturing expertise with Factor’s advanced gene-editing technology to develop innovative cell therapies for a range of serious medical conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106778477) on January 06, 2026, and is solely responsible for the information contained therein.